Analytical Data
-
Gene name
IL-36 alpha
- Application
-
Alternative Names
FIL1 epsilon, IL-1 epsilon, Interleukin-1 family member 6, IL-1F6, Interleukin-1 homolog 1
-
Species
Mouse
-
Source
E. coli
-
Tag
Tag Free
-
Purity
>95% as determined by SDS-PAGE
-
Uniprot
Q9JLA2
-
Expression Region
1-160aa
-
Molecular Weight
18.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-36 alpha, a member of the IL-1 cytokine family, has gained significant attention in recent years due to its pivotal role in immune responses and its association with various inflammatory conditions, particularly skin diseases such as psoriasis and atopic dermatitis. The protein is mainly produced by epithelial cells and plays a crucial part in the activation of innate immunity by promoting the expression of pro-inflammatory cytokines and chemokines. Researchers have been investigating the therapeutic potential of recombinant IL-36 alpha protein, aiming to understand its mechanisms of action in modulating immune responses. Studies have highlighted its ability to drive the activation and expansion of T helper 17 (Th17) cells, which are instrumental in chronic inflammation. Additionally, there is growing interest in the development of IL-36 alpha as a biomarker for inflammatory diseases, as its expression levels correlate with disease severity. Understanding the structure-function relationship of IL-36 alpha through recombinant protein studies can facilitate the development of targeted therapies, potentially leading to novel treatment strategies for patients suffering from IL-36 alpha-mediated diseases. Overall, the exploration of IL-36 alpha as a therapeutic target represents a promising avenue in the quest for innovative approaches to manage inflammatory disorders.
